指南与共识前列腺癌

晚期前列腺癌下一代影像学临床应用指南(RADAR III)

A Clinician's Guide to Next Generation Imaging in Patients With Advanced Prostate Cancer (RADAR III).
指南 / 共识 · J Urol · 2019-01-01

RADAR III专家组针对晚期前列腺癌下一代影像学应用提出指导,建议对基于实验室指标、合并症和症状怀疑疾病进展的特定患者使用下一代影像技术。目前18F-fluciclovine和68Ga-PSMA PET/CT在可及性、特异性和敏感性方面具有良好组合。下一代影像能检测既往无法发现的转移灶,可能重新定义前列腺癌进展阶段,从而通过早期系统或局部定向治疗改善患者结局。

要点

  • 对怀疑疾病进展的特定患者推荐下一代影像技术
  • 18F-fluciclovine和68Ga-PSMA PET/CT为目前优选下一代影像剂
  • 下一代影像可检测微转移,可能重新定义疾病进展阶段

核心结论

  • RADAR III专家组一致认为进展至转移性疾病是患者治疗的关键事件。
  • 下一代影像技术能检测既往无法检测的转移灶,可能重新定义前列腺癌进展阶段。
  • 早期系统或局部定向治疗可能积极改变患者结局。

研究设计与样本

  • RADAR(Radiographic Assessments for Detection of Advanced Recurrence)III专家组召开会议,基于现有数据和临床经验提供下一代影像用于前列腺癌分期的指导。
  • 专家组还讨论了下一代影像基于更早发现疾病对治疗选择的潜在影响。

主要发现

  • 下一代影像技术能够检测既往无法检测的转移灶。
  • 当前18F-fluciclovine和68Ga前列腺特异性膜抗原(PSMA)正电子发射断层/计算机断层(PET/CT)是具备良好可及性、特异性和敏感性组合的下一代影像剂。
  • 其他下一代影像技术正在研究中,可能提供更好的诊断准确性和治疗选择。

关键数值与推荐

  • RADAR III专家组建议对基于实验室(生物标志物)值、合并症和症状怀疑疾病进展的特定患者使用下一代影像技术。

临床怎么用

  • 临床医生应依据实验室(生物标志物)值、合并症和症状怀疑疾病进展时,考虑使用下一代影像技术进行分期。
  • 目前可优先考虑18F-fluciclovine或68Ga-PSMA PET/CT作为下一代影像剂。
  • 根据下一代影像检测到的更早转移信息,调整系统或局部定向治疗策略。

局限性

  • 常缺乏相关性治疗数据。
  • 下一代影像技术仍在演进,全球可及性有待提高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The advanced prostate cancer therapeutic landscape has changed dramatically in the last several years, resulting in improved overall survival of patients with castration naïve and castration resistant disease. The evolution and development of novel next generation imaging techniques will affect diagnostic and therapeutic decision making. Clinicians must navigate when and which next generation imaging techniques to use and how to adjust treatment strategies based on the results, often in the absence of correlative therapeutic data. Therefore, guidance is needed based on best available information and current clinical experience. MATERIALS AND METHODS: The RADAR (Radiographic Assessments for Detection of Advanced Recurrence) III Group convened to offer guidance on the use of next generation imaging to stage prostate cancer based on available data and clinical experience. The group also discussed the potential impact of next generation imaging on treatment options based on earlier detection of disease. RESULTS: The group unanimously agreed that progression to metastatic disease is a seminal event for patient treatment. Next generation imaging techniques are able to detect previously undetectable metastases, which could redefine the phases of prostate cancer progression. Thus, earlier systemic or locally directed treatment may positively alter patient outcomes. CONCLUSIONS: The RADAR III Group recommends next generation imaging techniques in select patients in whom disease progression is suspected based on laboratory (biomarker) values, comorbidities and symptoms. Currently 18F-fluciclovine and 68Ga prostate specific membrane antigen positron emission tomography/computerized tomography are the next generation imaging agents with a favorable combination of availability, specificity and sensitivity. There is ongoing research of additional next generation imaging technologies, which may offer improved diagnostic accuracy and therapeutic options. As next generation imaging techniques evolve and presumably result in improved global accessibility, clinician ability to detect micrometastases may be enhanced for decision making and patient outcomes.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Crawford ED, Koo PJ, Shore N, et al. A Clinician's Guide to Next Generation Imaging in Patients With Advanced Prostate Cancer (RADAR III). J Urol. 2019. PMID: 30077557. doi:10.1016/j.juro.2018.05.164

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。